ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups
The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study.
The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study.
What's Your Reaction?
